Delivery Order SPE2DR25D3005-SPE2DR26FP8NN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,807.47 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 8, 2026, with an ultimate completion date of January 9, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $4,724.33 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 12, 2026, with an ultimate completion date of January 13, 2026. This is a firm fixed-price, non-set-aside contract performed at the contractor's headquarters in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $26,892.34 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on January 7, 2026, with an ultimate completion date of January 8, 2026. This non-set-aside, competitively awarded contract utilizes firm fixed-price pricing and represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $13,116.80 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on January 6, 2026, with an ultimate completion date of January 7, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $13,061.94 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 8, 2026, for RINVOQ ER 15 mg tablets (30-count units), with final delivery due January 9, 2026. This non-set-aside award was competitively procured and is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The order represents a task order execution under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose) valued at $3,111.66 under a firm fixed-price contract. The award, announced on August 6, 2025, with an ultimate completion date of August 7, 2025, represents a non-competitive, non-set-aside delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order valued at $17,740.56 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 9, 2026, with a completion date of January 12, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award is issued under AmerisourceBergen's parent company Cencora, Inc.'s Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at...
- The Defense Logistics Agency awarded a $19,675.26 delivery order to AmerisourceBergen Drug Corp on January 13, 2026, for the supply of RINVOQ ER 15mg tablets (30-count bottles). This is a firm fixed-price, non-set-aside contract with a completion date of January 14, 2026, and performance location in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up...
- The Defense Logistics Agency awarded a delivery order valued at $3,279.20 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on January 13, 2026, with a completion date of January 14, 2026. This non-set-aside, competitively awarded contract was issued as a firm fixed-price delivery order and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major...
- The Defense Logistics Agency awarded a $10,152.31 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on December 11, 2025, with an ultimate completion date of December 12, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running through December 2026. The delivery will be...
- SPE2DR25D3005Indefinite Delivery Contract
- SPE2DR25D3005-SPE2DR26FP8NNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $108,228.44 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 12, 2026, with an ultimate completion date of January 13, 2026. This firm fixed-price, non-set-aside contract is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for supplying pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen, operating as a subsidiary of Cencora, Inc., is a major pharmaceutical distributor providing a comprehensive range of medications, vaccines, medical devices, and specialized healthcare commodities to federal agencies. The company has demonstrated capability to meet federal procurement requirements through competitive award processes, with contract awards typically structured as firm fixed-price delivery orders covering pharmaceutical products across multiple therapeutic domains. This delivery order for RINVOQ (upadacitinib), a treatment for rheumatologic and inflammatory conditions, reflects the company's role as a critical vendor for military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $108.2k | 1/11/26 |